PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman(Brigham and Women's Hospital), Gordon J. Freeman(Harvard University), Karen Bourque, Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Tasuku Honjo(Kyoto University), Raquel Nunes(Harvard University), Irene Chernova(Yale University), Laura Carter, Arlene H. Sharpe(Brigham and Women's Hospital), Divya Chaudhary(Jaypee Institute of Information Technology), Madhuri Borde(Brigham and Women's Hospital), Clive R. Wood, Nelly Malenkovich(Harvard University), Julia A. Brown(Cornell University), Andrew J. Long, Yoshiko Iwai(Nippon Medical School), Hiroyuki Nishimura(Kyoto University), Tatyana Chernova(University of Cambridge), Beatriz M. Carreno(California University of Pennsylvania), Edward Greenfield(Harvard University), Taku Okazaki(Tokushima University)
Cited by 2,948
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
|The Journal of Experimental Medicine|2000|5.2k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k
Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2)
|Cell|2000|1.6k
PD-1 and PD-1 ligands: from discovery to clinical application
|International Immunology|2007|1.3k